Brentuximab vedotin followed by bendamustine supercharge for refractory or relapsed Hodgkin lymphoma

We evaluated the impact on progression-free survival (PFS) of achieving a deep metabolic response at 2-deoxy-2[(18)F] fluoro-d-glucose positron emission tomography (FDG-PET) in patients with refractory or relapsed (R/R) classic Hodgkin lymphoma (cHL) following a new salvage regimen named Bv+Bs (bren...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Blood Adv
Auteurs principaux: Picardi, M., Della Pepa, R., Giordano, C., Pugliese, N., Mortaruolo, C., Trastulli, F., Rascato, M. G., Cappuccio, I., Raimondo, M., Memoli, M., Monteverde, M., Mascolo, M., Pane, F.
Format: Artigo
Langue:Inglês
Publié: American Society of Hematology 2019
Sujets:
Clinical Trials and Observations
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517654/
https://ncbi.nlm.nih.gov/pubmed/31088808
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000123
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires